Viyash Scientific, a Formulations, APIs and CDMO Services company, has reported that a net profit of ₹66 crore in the March quarter against net loss of ₹32 crore logged in the same period last year, on better demand and higher margin.

Revenue increased 19 per cent to ₹920 crore in the quarter under review. EBITDA was up 64 per cent at ₹200 crore.

In FY26, the company reported 14 times increase in net profit at ₹225 crore (₹16 crore). Revenue was up 14 per cent at ₹3,420 crore (₹3,007 crore) while EBITDA jumped 60 per cent to ₹702 crore (₹440 crore).

The Company also reported a Net Debt to EBITDA ratio of 0.2 times, reflecting a significantly deleveraged balance sheet and strong financial discipline.

Dr Hari Babu Bodepudi, Managing Director and Group CEO, Viyash Scientific said the March quarter was the strongest quarter in the company’s history, with merger synergies beginning to reflect meaningfully in financial performance.

The integrated platform has strengthened execution, improved operating leverage and enhanced our resilience amid ongoing geopolitical and maritime disruptions, he said.

“We continue to navigate these challenges through disciplined asset utilization, cost controls and agile pricing strategies. As we enter FY27, we are excited about our product pipeline and growth roadmap,” he added.

With a significantly deleveraged balance sheet, the company is also actively evaluating selective inorganic opportunities to further strengthen the platform and create long-term value, said Bodepudi.

Viyash Scientific ranks among the top 25 Animal Health companies globally and has over 3,000 employees.

The company is an integrated pharmaceutical enterprise with a strong portfolio of formulations and APIs for both human and veterinary use, serving customers in more than 100 countries.

Viyash Scientific and its subsidiaries have manufacturing, R&D and distribution operations across India, Spain, Brazil, Turkey and the US, with approvals from leading international regulatory authorities including the USFDA, EUGMP, WHO and TGA.

Shares of the company were up one per cent at ₹229 on Tuesday.

Published on May 20, 2026